Roivant reports Q2 net loss $316M; VTAMA net revenue $5M; cash runway extended to H2 2025

Roivant Sciences Ltd.

2022-Q2 EPS reported -$0.89 revenue$16,852,000

Net loss $315.9M ($0.42/share); non-GAAP net loss $226.8M improved from $290.0M YoY.
VTAMA net product revenue $5.0M; over 54,000 prescriptions by ~6,400 prescribers since launch.
Cash, equivalents and restricted cash $1.6B; runway extended to H2 2025 after offerings and Myovant proceeds.
Completed enrollment for brepocitinib SLE potentially registrational trial; data H2 2023.
Federal court denied Moderna's motion to dismiss Genevant/Arbutus IP suit; discovery proceeds.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Roivant Sciences Ltd. reported fiscal quarter ended September 30, 2022 results: revenue $5.0 million.

Period: fiscal quarter ended September 30, 2022
Revenue: $5.0 million
Result: reported results

Exact text from the filing

Roivant reported VTAMA net product revenue of $5.0 million, representing a gross-to-net yield of approximately 12%.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-22-041169

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.